EBS EMERGENT BIOSOLUTIONS INC revenue, earnings and financials

For the quarter ended June 30, 2026, EMERGENT BIOSOLUTIONS INC reported revenue of $234M (up 66.3% from a year earlier), net income of −$180M and diluted EPS of −$3.49; over the last four quarters revenue was $770M and net income −$177M; for the fiscal year ended December 2025 revenue was $743M, down 28.8% on the year before.

EBS annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $743M, gross profit n/a, operating income $100M, net income $52.6M (margin 7.1%), EPS $0.93
• Fiscal year ended Dec 2024: revenue $1.04B, gross profit n/a, operating income −$109M, net income −$191M (margin -18.3%), EPS −$3.60
• Fiscal year ended Dec 2023: revenue $1.05B, gross profit $318M, operating income −$726M, net income −$761M (margin -72.5%), EPS −$14.85
• Fiscal year ended Dec 2022: revenue $1.12B, gross profit $383M, operating income −$170M, net income −$212M (margin -18.9%), EPS −$4.22
• Fiscal year ended Dec 2021: revenue $1.77B, gross profit $891M, operating income $341M, net income $220M (margin 12.4%), EPS $4.06

EBS quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $234M (up 66.3% year over year), net income −$180M, EPS −$3.49
• Quarter ended Mar 31, 2026: revenue $156M (down 29.7% year over year), net income $6.80M, EPS $0.07
• Quarter ended Dec 31, 2025 (from the annual report): revenue $149M (down 23.6% year over year), net income −$54.6M, EPS −$0.95
• Quarter ended Sep 30, 2025: revenue $231M (down 21.3% year over year), net income $51.2M, EPS $0.91
• Quarter ended Jun 30, 2025: revenue $141M (down 44.7% year over year), net income −$12.0M, EPS −$0.22
• Quarter ended Mar 31, 2025: revenue $222M (down 26.0% year over year), net income $68.0M, EPS $1.19
• Quarter ended Dec 31, 2024 (from the annual report): revenue $195M (down 29.6% year over year), net income −$31.3M, EPS −$0.45
• Quarter ended Sep 30, 2024: revenue $294M (up 8.6% year over year), net income $115M, EPS $2.06
• Quarter ended Jun 30, 2024: revenue $255M (down 24.6% year over year), net income −$283M, EPS −$5.38
• Quarter ended Mar 31, 2024: revenue $300M (up 82.8% year over year), net income $9.00M, EPS $0.17
• Quarter ended Dec 31, 2023 (from the annual report): revenue $277M (down 16.2% year over year), net income −$49.5M, EPS −$0.90
• Quarter ended Sep 30, 2023: revenue $271M (up 12.8% year over year), net income −$263M, EPS −$5.08
• Quarter ended Jun 30, 2023: revenue $338M (up 39.3% year over year), net income −$261M, EPS −$5.16
• Quarter ended Mar 31, 2023: revenue $164M (down 46.1% year over year), net income −$186M, EPS −$3.71
• Quarter ended Dec 31, 2022: revenue $330M (down 54.9% year over year), net income −$67.0M, EPS −$1.34
• Quarter ended Sep 30, 2022: revenue $240M (down 16.2% year over year), net income −$87.1M, EPS −$1.75
• Quarter ended Jun 30, 2022: revenue $243M (down 35.7% year over year), net income −$52.9M, EPS −$1.06
• Quarter ended Mar 31, 2022: revenue $305M (down 19.2% year over year), net income −$4.60M, EPS −$0.09
• Quarter ended Dec 31, 2021: revenue $733M, net income $193M, EPS $3.60
• Quarter ended Sep 30, 2021: revenue $286M, net income −$40.4M, EPS −$0.75

EBS cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $171M, share buybacks $24.9M
• Fiscal year ended Dec 2024: operating cash flow $58.7M, share buybacks $0
• Fiscal year ended Dec 2023: operating cash flow −$206M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow −$34.1M, share buybacks $82.1M
• Fiscal year ended Dec 2021: operating cash flow $320M, share buybacks $106M

EBS balance sheet

• Jun 30, 2026: cash $140M, total assets $1.12B, total liabilities $775M, shareholders' equity $341M, long-term debt $582M
• Mar 31, 2026: cash $160M, total assets $1.32B, total liabilities $797M, shareholders' equity $523M, long-term debt $574M
• Dec 31, 2025: cash $205M, total assets $1.32B, total liabilities $796M, shareholders' equity $523M, long-term debt $572M
• Sep 30, 2025: cash $246M, total assets $1.46B, total liabilities $879M, shareholders' equity $583M, long-term debt $663M
• Jun 30, 2025: cash $267M, total assets $1.42B, total liabilities $881M, shareholders' equity $536M, long-term debt $668M
• Mar 31, 2025: cash $149M, total assets $1.43B, total liabilities $873M, shareholders' equity $553M, long-term debt $666M
• Dec 31, 2024: cash $99.5M, total assets $1.39B, total liabilities $907M, shareholders' equity $483M, long-term debt $664M
• Sep 30, 2024: cash $150M, total assets $1.48B, total liabilities $969M, shareholders' equity $508M, long-term debt $662M

What is EBS's revenue?

EMERGENT BIOSOLUTIONS INC reported $770M of revenue over its last four quarters, through June 30, 2026.

Is EBS profitable?

No. EMERGENT BIOSOLUTIONS INC lost $177M over the last four quarters.

What is EBS's EPS?

Diluted earnings per share over the last four quarters were −$3.46; −$3.49 in the latest quarter.

EBS ownership and insider trades · All stocks